Drug Profile
Research programme: proinsulin-transferrin fusion protein - Ventria Bioscience
Alternative Names: ProINS-TfLatest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Ventria Bioscience
- Developer University of North Carolina; Ventria Bioscience
- Class Recombinant fusion proteins
- Mechanism of Action Ornithine decarboxylase stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Diabetes mellitus
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for research development in Diabetes-mellitus in USA
- 12 Feb 2013 Ventria Bioscience and the University of Southern California receive SBIR grant from the US National Institutes of Health for proinsulin-transferrin fusion protein development in Diabetes mellitus
- 12 Feb 2013 Early research in Diabetes mellitus in USA (unspecified route)